ReviewCurrent gastroenterology reports2015
Next-Generation Therapeutics for IBD.
Review in Current gastroenterology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Angiogenesis in Inflammatory Bowel Disease.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Lymphocyte homing disorder: a concealed driver of intestinal immune collapse in sepsis.Frontiers in immunology · 2026Review
- Contribution of Blood Vessel Activation, Remodeling and Barrier Function to Inflammatory Bowel Diseases.International journal of molecular sciences · 2023Review
- Probiotics in Intestinal Mucosal Healing: A New Therapy or an Old Friend?Pharmaceuticals (Basel, Switzerland) · 2021Review
- A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis.Inflammatory intestinal diseases · 2021Article
- Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries.Gut and liver · 2020Review
- A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD.Inflammatory bowel diseases · 2019Review
- The Association Between Arthralgia and Vedolizumab Using Natural Language Processing.Inflammatory bowel diseases · 2018Observational
- Hydrogen peroxide production by lactobacilli promotes epithelial restitution during colitis.Redox biology · 2018Article
- Novel treatments for inflammatory bowel disease.The Korean journal of internal medicine · 2018Review
- Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.Drugs & aging · 2017Article
- A vitamin D receptor agonist converts CD4+ T cells to Foxp3+ regulatory T cells in patients with ulcerative colitis.Oncotarget · 2017Article
- Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD.Inflammatory bowel diseases · 2017Article
- Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis.Journal of visualized experiments : JoVE · 2017Article
- Investigation of JAKs/STAT-3 in lipopolysaccharide-induced intestinal epithelial cells.Clinical and experimental immunology · 2016Article
- The Role of Neuropeptides in Mouse Models of Colitis.Journal of molecular neuroscience : MN · 2016Review
- Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.Current gastroenterology reports · 2016Review
- Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications.World journal of gastroenterology · 2016Review
- Advances in the development of new biologics in inflammatory bowel disease.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various novel drugs have recently been evaluated in clinical trials showing promising effects in patients with inflammatory bowel disease (IBD). Here, we summarize the recent literature in the area of emerging therapies in the field of IBD, with specific focus on anti-integrin antibodies, such as vedolizumab (anti-α4β7) and etrolizumab (anti-rhuMAb β7), and the Janus kinase (JAK) inhibitor tofacitinib. Moreover, we will discuss efficacy and safety data of golimumab (a new subcutaneous anti-tumor necrosis factor (TNF) antibody), Avaxia (an orally delivered anti-TNF antibody), and Budesonide MMX; all have been developed for the treatment of ulcerative colitis. Other therapeuticals that might find their way to the market the coming years include the anti-mucosal vascular addressin cell adhesion molecule (MAdCAM) PF-00547659, small molecules (including laquinimod and the CCR9 antagonist Vercirnon), as well as an orally active SMAD7 antisense oligonucleotide that showed clinical benefit in Crohn's disease patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.